دورية أكاديمية
The cascade of care for hepatitis C in Victoria, Australia: a data linkage cohort study.
| العنوان: | The cascade of care for hepatitis C in Victoria, Australia: a data linkage cohort study. |
|---|---|
| المؤلفون: | Snow K; WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., MacLachlan JH; WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia., Rowe S; Victorian Government Department of Health, Melbourne, Victoria, Australia.; School of Population Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia., Higgins N; Victorian Government Department of Health, Melbourne, Victoria, Australia., Cowie BC; WHO Collaborating Centre for Viral Hepatitis, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Infectious Diseases, University of Melbourne, Melbourne, Victoria, Australia.; Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Victoria, Australia. |
| المصدر: | Internal medicine journal [Intern Med J] 2024 Jul; Vol. 54 (7), pp. 1146-1154. Date of Electronic Publication: 2024 Mar 19. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Science Asia Country of Publication: Australia NLM ID: 101092952 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1445-5994 (Electronic) Linking ISSN: 14440903 NLM ISO Abbreviation: Intern Med J Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Carlton, Vic. : Blackwell Science Asia, c2001- |
| مواضيع طبية MeSH: | Hepatitis C*/epidemiology , Hepatitis C*/therapy , Hepatitis C*/drug therapy, Humans ; Female ; Male ; Middle Aged ; Victoria/epidemiology ; Adult ; Aged ; Cohort Studies ; Longitudinal Studies ; Registries ; Young Adult ; Information Storage and Retrieval ; Antiviral Agents/therapeutic use ; Adolescent ; Hepatitis C, Chronic/epidemiology ; Hepatitis C, Chronic/drug therapy ; Health Services Accessibility |
| مستخلص: | Background: Highly effective hepatitis C therapies are available in Australia. However, people living with hepatitis C face various barriers to accessing care and treatment. Aims: To identify gaps in the cascade of care for hepatitis C and generate estimates of the number living with untreated infection according to population group, using a representative longitudinal study population. Methods: We linked hepatitis C notification data from Victoria to national pathology, prescribing and death registry data. We assessed receipt of key clinical services in a large cohort who tested positive for hepatitis C from 1 January 2000 to 31 December 2016, with follow-up to 30 June 2018. We estimated the number still living with hepatitis C, adjusting for spontaneous clearance and mortality. Results: The cohort comprised 45 391 people positive for hepatitis C. Of these, 13 346 (29%) received treatment and an estimated 28% (95% confidence interval (CI): 26-30%) were still living with chronic infection at 30 June 2018, with the remainder still living following spontaneous clearance (30%, 95% CI: 29-32%) or having died (12%, 95% CI: 12-12%). Half (50%) of those still living with hepatitis C were born from 1965 to 1980, and 74% first tested positive before 2011. Conclusions: Despite an enabling policy environment and subsidised therapy, many people in this cohort were not treated. Increased measures may be needed to engage people in care, including those who acquired hepatitis C more than 10 years ago. (© 2024 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.) |
| References: | Australian Government Department of Health. Schedule of Pharmaceutical Benefits Summary of Changes March 2016 Canberra: Commonwealth of Australia; 2016. Available from URL: http://www.pbs.gov.au/publication/schedule/2016/03/2016-03-01-general-schedule-soc.pdf. Hajarizadeh B, Grebely J, Matthews GV, Martinello M, Dore GJ. Uptake of direct‐acting antiviral treatment for chronic hepatitis C in Australia. J Viral Hepat 2018; 25: 640–648. The Kirby Institute. Monitoring Hepatitis C Treatment Uptake in Australia: Issue 12. July 2022. Report No. 2022. Australian Institute of Health and Welfare. The First Year of COVID‐19 in Australia: Direct and Indirect Health Effects; 2021. MacLachlan J, Stewart S, Cowie B. Viral Hepatitis Mapping Project: Geographic Diversity in Chronic Hepatitis B and C Prevalence, Management and Treatment. National Report 2020. Darlinghurst, NSW: ASHM; 2021. World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Geneva: World Health Organization; 2021. Razavi H, Sanchez Gonzalez Y, Yuen C, Cornberg M. Global timing of hepatitis C virus elimination in high‐income countries. Liver Int 2020; 40: 522–529. Hajarizadeh B, Grebely J, McManus H, Estes C, Razavi H, Gray RT et al. Chronic hepatitis C burden and care cascade in Australia in the era of interferon‐based treatment. J Gastroenterol Hepatol 2017; 32: 229–236. Snow K, Scott N, Clothier HJ, MacLachlan JH, Cowie B. Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001‐2012: a multi‐level modelling analysis. Aust N Z J Public Health 2017; 41: 193–198. Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy 2017; 47: 107–116. The Kirby Institute. Monitoring Hepatitis C Treatment Uptake in Australia: Issue 12. 2021 July 2022. Report No. 5. Burnet Institute and Kirby Institute. Australia's Progress towards Hepatitis C Elimination: Annual Report 2022. Melbourne: Burnet Institute and Kirby Institute; 2022. Razali K, Thein HH, Bell J, Cooper‐Stanbury M, Dolan K, Dore G et al. Modelling the hepatitis C virus epidemic in Australia. Drug Alcohol Depend 2007; 91: 228–235. MacLachlan JRN, Higgins N, Coutts R, Chan R, Stephens N, Cowie BC. Epidemiology of chronic hepatitis B and C in Victoria, Australia: insights and impacts from enhanced surveillance. Aust N Z J Public Health 2020; 44: 59–64. MacLachlan JH, Smith C, Towell V, Cowie BC. Viral Hepatitis Mapping Project: National Report 2018‐19. Sydney: The Doherty Institute; 2020. Scott N, Hainsworth SW, Sacks‐Davis R, Pedrana A, Doyle J, Wade A et al. Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access. J Virus Erad 2018; 4: 108–114. Public Health and Wellbeing Act, Parliament of Victoria (2008). National Notifiable Diseases Surveillance System. Canberra: Department of Health, Australian Government; 2018 [2018 Jul 11]. Available from URL: http://www9.health.gov.au/cda/source/cda-index.cfm. Australian Government Department of Health. Australian National Notifiable Diseases and Case Definitions; 2017 [2018 Mar 27]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/Content/cdna-casedefinitions.htm. Australian Government Department of Health. Medicare; 2022. Available from URL: https://www.health.gov.au/health-topics/medicare. Australian Government Department of Health. About the PBS; 2022. Available from URL: https://www.pbs.gov.au/info/about-the-pbs. Aisyah DN, Shallcross L, Hully AJ, O'Brien A, Hayward A. Assessing hepatitis C spontaneous clearance and understanding associated factors‐a systematic review and meta‐analysis. J Viral Hepat 2018; 25: 680–698. The Kirby Institute. Monitoring Hepatitis C Treatment Uptake in Australia: Issue 11. July 2021. Report No. 5. Iversen J, Dore GJ, Starr M, Catlett B, Cunningham P, Geddes L et al. Estimating the consensus hepatitis C cascade of care among people who inject drugs in Australia: pre and post availability of direct acting antiviral therapy. Int J Drug Policy 2020; 83: 102837. Couto ECC, Salom CL, Dietze P, Lenton S, Burns L, Alati R. Frequent experience of discrimination among people who inject drugs: links with health and wellbeing. Drug Alcohol Depend 2018; 190: 188–194. Treloar C, Rance J, Backmund M. Understanding barriers to hepatitis C virus care and stigmatization from a social perspective. Clin Infect Dis 2013; 57: 51–55. Goutzamanis S, Doyle JS, Horyniak D, Higgs P, Hellard M, TAP study group. Peer to peer communication about hepatitis C treatment amongst people who inject drugs: a longitudinal qualitative study. Int J Drug Policy 2020; 87: 102983. Wright C, Cogger S, Hsieh K, Goutzamanis S, Hellard M, Higgs P. “I'm obviously not dying so it's not something I need to sort out today”: considering hepatitis C treatment in the era of direct acting antivirals. Infect Dis Health 2019; 24: 58–66. Scarborough J, Miller ER, Aylward P, Eliott J. “Sussing that doctor out.” Experiences and perspectives of people affected by hepatitis C regarding engagement with private general practitioners in South Australia: a qualitative study. BMC Fam Pract 2017; 18: 97. Marshall AD, Grebely J, Dore GJ, Treloar C. Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists—the practitioner experience. Drug Alcohol Depend 2020; 206: 107705. Pourmarzi D, Smirnov A, Hall L, Thompson H, FitzGerald G, Rahman T. Enablers and barriers for the provision of community‐based HCV treatment: a case study of a real‐world practice. J Viral Hepat 2020; 27: 484–496. Litwin AH, Drolet M, Nwankwo C, Torrens M, Kastelic A, Walcher S et al. Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: the C‐SCOPE study. J Viral Hepat 2019; 26: 1094–1104. Heard E, Massi L, Smirnov A, Selvey LA. Prescribing direct‐acting antivirals to treat hepatitis C virus in a general practice setting in Australia: ‘so why not do it’? Intern Med J 2020; 50: 1053–1058. WHO Collaborating Centre for Viral Hepatitis at The Doherty Institute. CHECCS Project Evaluation Report Melbourne: The Doherty Institute; 2022. Available from URL: https://www.doherty.edu.au/whoccvh/centre-activities/checcs. Allard NL, MacLachlan JH, Cowie BC. The cascade of care for Australians living with chronic hepatitis B: measuring access to diagnosis, management and treatment. Aust N Z J Public Health 2015; 39: 255–259. |
| معلومات مُعتمدة: | PG-14-2016 Royal Melbourne Hospital Foundation |
| فهرسة مساهمة: | Keywords: antiviral treatment; data linkage; epidemiology; hepatitis C |
| المشرفين على المادة: | 0 (Antiviral Agents) |
| تواريخ الأحداث: | Date Created: 20240320 Date Completed: 20240716 Latest Revision: 20240716 |
| رمز التحديث: | 20240717 |
| DOI: | 10.1111/imj.16361 |
| PMID: | 38504432 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1445-5994 |
|---|---|
| DOI: | 10.1111/imj.16361 |